Here are the 10-K annual reports from Syndax Pharmaceuticals, Inc. (SNDX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SNDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNDX filings page.
Syndax Pharmaceuticals is a commercial-stage biopharma company focused on cancer and fibrotic diseases, now built around two FDA‑approved medicines and a broad development pipeline.
The company markets Revuforj (revumenib), a first‑in‑class oral menin inhibitor approved in the United States for relapsed or refractory acute leukemia with a KMT2A translocation and for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in patients one year and older who lack satisfactory alternatives. Revuforj is being studied across the acute leukemia treatment continuum in multiple Phase 1–3 trials, including pivotal frontline combinations with venetoclax, azacitidine and intensive chemotherapy, and early programs in myelofibrosis and minimal residual disease.
Niktimvo (axatilimab‑csfr), a first‑in‑class CSF‑1R‑blocking antibody, is approved for chronic graft‑versus‑host disease after at least two prior systemic therapies in adults and pediatric patients weighing at least 40 kg. It showed a 75% overall response rate at the approved dose in the AGAVE‑201 study and is being co‑commercialized with Incyte in the United States, with Incyte holding ex‑U.S. rights. Axatilimab is in clinical development for newly diagnosed chronic GVHD and idiopathic pulmonary fibrosis.
The business is supported by multiple global license agreements for its core assets, extensive patent estates extending into the 2030s and 2040s, and a significant royalty financing with Royalty Pharma, which provided an upfront $350 million in exchange for a capped percentage of future U.S. axatilimab net sales.